Alnylam planning revusiran Phase III

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said results from a Phase II study of its RNAi therapeutic revusiran ( ALN-TTRsc) to treat transthyretin (TTR) cardiac amyloidosis support advancement into Phase III. The company expects to start that trial by year end.

In the Phase II study, five weeks of revusiran produced an 87.2% mean maximum knockdown of TTR, including a knockdown of up to 98.2% -- the highest seen for a clinical RNAi therapeutic, according to the company. ...